Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ: MDGL) plans to announce the topline results from its Phase 3 MAESTRO-NAFLD-1 study of resmetirom on January 31, 2022, at 7:00 am EST. The subsequent conference call is scheduled for 8:00 am EST the same day. This study aims to provide insights into resmetirom's effectiveness for treating fatty liver diseases, particularly non-alcoholic steatohepatitis (NASH). Resmetirom is a first-in-class, liver-directed, thyroid hormone receptor (THR)-β selective agonist currently evaluated in two Phase 3 trials.

Positive

• Phase 3 clinical study MAESTRO-NAFLD-1 results announcement scheduled for January 31, 2022.
• Resmetirom targets unmet medical needs in fatty liver diseases and NASH patients.

Negative

• None.

CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on Monday, January 31^st, 2022.

The schedule for the press release and conference call/webcast is as follows:

• MAESTRO-NAFLD-1 Press Release:		January 31st, 2022 at 7:00 am EST
• MAESTRO-NAFLD-1 Conference Call:		January 31st, 2022 at 8:00 am EST
• Domestic Dial-In Number:		(833) 660-2754
• International Dial-In Number:		(409) 350-3497
• Conference ID Number:		9170277

To access the live webcast of the call please visit the Events and Presentations section of Madrigal’s website or click here. An archived webcast will be available on the Madrigal website after the event.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of fatty liver and cardio-metabolic diseases with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-β selective agonist that is currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in NASH (non-alcoholic steatohepatitis) patients. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com 

FAQ

What is the purpose of the MAESTRO-NAFLD-1 study by Madrigal Pharmaceuticals?

The MAESTRO-NAFLD-1 study is designed to evaluate the efficacy of resmetirom in treating fatty liver diseases, specifically focusing on non-alcoholic steatohepatitis (NASH).

When will the topline results for the MAESTRO-NAFLD-1 study be announced?

The topline results for the MAESTRO-NAFLD-1 study will be announced on January 31, 2022.

What is resmetirom and its significance?

Resmetirom is a first-in-class, orally administered thyroid hormone receptor (THR)-β selective agonist targeting fatty liver diseases and has the potential to address significant unmet medical needs.

What are the next steps after the MAESTRO-NAFLD-1 results are released?

The next steps will depend on the outcomes from the MAESTRO-NAFLD-1 study, which may influence further clinical development, regulatory submissions, and market strategies for resmetirom.